Literature DB >> 22796799

Epidemiology of the transition from early to late Crohn's disease.

Edouard Louis1.   

Abstract

Phenotypically, the transition from early to late Crohn's disease is characterized by the occurrence of complications including strictures, intra-abdominal fistulas and perianal fistulas, all of them leading to various types of surgeries and currently non-reversible tissue damage. It must, however, be kept in mind that this transition is not at all a uniform and linear process. According to these simple phenotypic criteria, Crohn's disease can already be a late disease at diagnosis while in other patients, it can still be an early disease after 20 years of evolution. This simply highlights the relativity of time in this field, actually reflecting the nature, location and severity of the inflammatory process. The risk over time of the development of these complications has been described, first in cohort studies and then in population-based studies. Globally, at diagnosis, between 19 and 38% only of Crohn's disease patients have complicated Crohn's disease. After 10 years, between 56 and 65% of patients have developed either stricturing or penetrating complications. After 20 years, these numbers are between 61 and 88%. In parallel to these structural changes, changes in the immunobiology of the disease also seem to occur; the latter seem to happen quicker with major modification already within 2 years of the diagnosis. Beside these general figures, important questions remain pending. First, the real timing of these changes is still unclear. Second, the precise role of genetics and environment in the development of these changes remains to be clarified. Third, the correlation between changes in immunobiology and intestinal structural damages has not been specifically studied.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22796799     DOI: 10.1159/000338129

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  7 in total

Review 1.  Surgical Management of Complex Enteric Fistulas in Crohn's Disease.

Authors:  Luiz Felipe de Campos-Lobato; Ravi P Kiran
Journal:  Clin Colon Rectal Surg       Date:  2019-07-02

2.  Alleviated mucosal and neuronal damage in a rat model of Crohn's disease.

Authors:  Petra Talapka; Lajos István Nagy; Alexandra Pál; Marietta Zita Poles; Anikó Berkó; Mária Bagyánszki; László Géza Puskás; Éva Fekete; Nikolett Bódi
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

3.  Outcomes of computed tomography and magnetic resonance enterography in clinical practice of inflammatory bowel disease.

Authors:  Niraj S Patel; Suresh Pola; Ramya Muralimohan; G Y Zou; Cynthia Santillan; Derek Patel; Barrett G Levesque; William J Sandborn
Journal:  Dig Dis Sci       Date:  2013-12-10       Impact factor: 3.199

Review 4.  The Emerging Adult with Inflammatory Bowel Disease: Challenges and Recommendations for the Adult Gastroenterologist.

Authors:  Itishree Trivedi; Laurie Keefer
Journal:  Gastroenterol Res Pract       Date:  2015-05-04       Impact factor: 2.260

Review 5.  Transition of pediatric to adult care in inflammatory bowel disease: Is it as easy as 1, 2, 3?

Authors:  Anita Afzali; Ghassan Wahbeh
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

6.  The Diagnostic Role of Magnetic Resonance Enterography as a Complementary Test to Colonoscopy in Active Crohn's Disease.

Authors:  Arvin Aryan; Zahra Azizi; Azam Teimouri; Nasser Ebrahimi Daryani; Najme Aletaha; Ali Jahanbakhsh; Mohammad Kazem Nouritaromlou; Forough Alborzi; Masoud Mami; Vahid Basirat; Sanam Javid Anbardan
Journal:  Middle East J Dig Dis       Date:  2016-04

7.  The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies.

Authors:  David T Rubin; Jenny Griffith; Qisu Zhang; Zsolt Hepp; Allison Keshishian
Journal:  Inflamm Bowel Dis       Date:  2021-07-27       Impact factor: 5.325

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.